Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients.



We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated "a little worse" and those rated "unchanged" on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living.



The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening.



Clinically meaningful change is measurable on the PSPRS over 6 months. © 2016 International Parkinson and Movement Disorder Society.
Neurosciences Department, Alfred Hospital, Melbourne, Victoria, Australia. sarah.hewer@dhhs.tas.gov.au.
Sarah
S
Hewer
Neurosciences Department, Alfred Hospital, Melbourne, Victoria, Australia.
Sue
S
Varley
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Adam L
AL
Boxer
Department of Epidemiology and Preventive Medicine, Clinical Haematology Department, Alfred Hospital, Monash University, Melbourne, Victoria, Australia.
Eldho
E
Paul
Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
David R
DR
Williams
D000368:Aged; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000071081:Minimal Clinically Important Difference; D009842:Oligopeptides / Q000494:pharmacology*; D012720:Severity of Illness Index; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy*
D009842:Oligopeptides; C425904:davunetide
minimal clinically important change (MCIC); progressive supranuclear palsy (PSP); progressive supranuclear palsy rating scale (PSPRS)